

Pharmacy Program Updates: Quarterly Pharmacy Changes Effective Oct. 1, 2022 – Part 1

IMPORTANT PHARMACY BENEFIT REMINDERS

Jan. 1, 2022 is the start of a new year and renewed or new health insurance benefits for most Blue Cross and Blue Shield of Texas (BCBSTX) members. As you see your patients, please consider the following reminders:

- Members' benefits may be based on a new drug list when their plans renew in 2022.
- Discuss your patients' benefits during an office visit or confirm their benefits by calling the number on their ID cards.
- Review the prescription drug list before prescribing medications.
- If your patients need a coverage exception or prior authorization request in order to take a
 medicine that may be excluded from coverage or included in a utilization management program,
 please visit the Prior Authorization/Step Therapy Programs section of our provider website at
 bcbstx.com/provider for the form and more information.

Treatment decisions are *always* between you and your patients. Coverage is subject to the terms and limits of your patients' benefit plans. Please advise them to review their benefit materials for details.

DRUG LIST CHANGES

Based on the availability of new prescription medications and Prime's National Pharmacy and Therapeutics Committee's review of changes in the pharmaceuticals market, some revisions (drugs still covered but moved to a higher out-of-pocket payment level) and/or exclusions (drugs no longer covered) will be made to the BCBSTX drug lists. Your patient(s) may ask you about therapeutic or lower cost alternatives if their medication is affected by one of these changes. **Changes effective Oct. 1, 2022 are outlined below.**

The October Quarterly Pharmacy Changes Part 2 article with more recent coverage additions will also be published closer to the October 1 effective date.

Please note: The drug list changes listed below apply only to some members whose health plan has a quarterly updated prescription drug list.

BCBSTX members on the Basic Annual, Multi-Tier Basic Annual, Enhanced Annual, Multi-Tier Enhanced Annual or Performance Annual Drug Lists will not have the revisions and/or exclusions applied until on or after Jan. 1, 2023.

Drug List Updates (Revisions/Exclusions) – As of Oct. 1, 2022

Non-Preferred Brand ¹	Drug Class/ Condition Used	Preferred Generic Alternative(s) ²	Preferred Brand Alternative(s) ^{1, 2}
	For		
Basic, Multi-Tier Basic, Enhanced and Multi-Tier Enhanced Drug Lists Revisions		J Lists Revisions	
CYSTADANE (betaine	Homocystinuria	There is a generic equival	ent available. Please talk
powder for oral solution)		to your doctor or pharmac	
		medication(s) available for	r your condition.
VIMPAT (lacosamide tab 50	Seizures	There is a generic equival	
mg, 100 mg, 150 mg, 200,		to your doctor or pharmac	
mg)		medication(s) available for	r your condition.

Multi-Tier E	Basic and Multi-Tie	r Enhanced Drug Lists Re	visions
DEXAMETHASONE	Inflammatory	methylprednisolone	
(dexamethasone tab 0.5 mg,	Conditions	tablets, prednisone	
0.75 mg)		tablets	
Drug ¹	Drug Class/ Condition Used For	Generic Alternatives ^{1,2}	Brand Alternatives ^{1,2}
Balanced, Perf		ormance Select Drug Lists	s Revisions
DEXAMETHASONE	Inflammatory	methylprednisolone	
(dexamethasone tab 0.5 mg,	Conditions	tablets, prednisone	
0.75 mg)		tablets	
MORPHINE SULFATE	Pain	morphine sulfate	
(morphine sulfate oral soln		solution 10 mg/5 ml	
20 mg/5 ml)			
MORPHINE SULFATE ER (morphine sulfate cap er 24hr 10 mg, 20 mg, 30 mg, 50 mg, 60 mg, 80 mg, 100 mg)	Pain	Please talk to your doctor medication(s) available for	
QUINIDINE SULFATE (quinidine sulfate tab 200 mg, 300 mg)	Arrhythmia	Please talk to your doctor medication(s) available for	
SULFADIAZINE (sulfadiazine tab 500 mg)	Infections	Please talk to your doctor medication(s) available for	
TRAMADOL HCL ER	Pain	Please talk to your doctor	•
(tramadol hcl tab er 24hr		medication(s) available for	•
biphasic release 100 mg,			,
200 mg, 300 mg)			
TRIHEXYPHENIDYL HCL	Parkinson's	Please talk to your doctor	or pharmacist about other
(trihexyphenidyl hcl oral soln 0.4 mg/ml)	Disease, Extrapyramidal Disorders	medication(s) available for	
VANDAZOLE	Bacterial	metronidazole vaginal	
(metronidazole vaginal gel 0.75%)	Vaginosis	gel 0.75%	
Balance	and Performance	e Select Drug Lists Revisi	ions
MOXIFLOXACIN	Antibacterial-	ciprofloxacin ophthalmic	
HYDROCHLORIDE	Ophthalmic	solution, gatifloxacin	
(moxifloxacin hcl ophth soln	5	ophthalmic solution,	
0.5% (base eq) (2 times		ofloxacin ophthalmic	
daily))		solution, moxifloxacin	
,,,		ophthalmic solution	
		· ·	
		ug List Revisions	
ZOLPIDEM TARTRATE	Insomnia	eszopiclone tablets,	
(zolpidem tartrate sl tab 1.75		zaleplon capsules,	
mg, 3.5 mg)		zolpidem tablets	
Ralancad Part	ormanco and Dorfo	ormance Select Drug Lists	Exclusions
BIDIL (isosorbide dinitrate-	Heart Failure	There is a generic equival	
hydralazine hcl tab 20-37.5		to your doctor or pharmaci	
mg)		medication(s) available for	
ופייי	1		jear condition.



CONTRAVE (naltrexone	Weight Loss	Qsymia, Saxenda,	
hcl-bupropion hcl tab er 12hr	-	Wegovy	
8-90 mg)			
ESBRIET (pirfenidone tab	Idiopathic	There is a generic equival	ent available. Please talk
267 mg, 801 mg)	Pulmonary	to your doctor or pharmac	
	Fibrosis	medication(s) available for	r your condition.
FERRIPROX (deferiprone	Transfusional	There is a generic equival	
tab 1000 mg)	Iron Overload	to your doctor or pharmac	ist about other
		medication(s) available for	r your condition.
K-PHOS (potassium	Urinary	There is a generic equival	ent available. Please talk
phosphate monobasic tab	Acidification	to your doctor or pharmac	ist about other
500 mg)		medication(s) available for	r your condition.
SAMSCA (tolvaptan tab 15	Hyponatremia	There is a generic equival	ent available. Please talk
mg)		to your doctor or pharmac	
		medication(s) available for	
STALEVO 50 (carbidopa-	Parkinson's	There is a generic equival	ent available. Please talk
levodopa-entacapone tabs	Disease	to your doctor or pharmac	ist about other
12.5-50-200 mg)		medication(s) available for	
STALEVO 75 (carbidopa-	Parkinson's	There is a generic equival	
levodopa-entacapone tabs	Disease	to your doctor or pharmac	
18.75-75-200 mg)		medication(s) available for	
STALEVO 100 (carbidopa-	Parkinson's	There is a generic equival	
levodopa-entacapone tabs	Disease	to your doctor or pharmac	
25-100-200 mg)		medication(s) available for	
STALEVO 125 (carbidopa-	Parkinson's	There is a generic equival	
levodopa-entacapone tabs	Disease	to your doctor or pharmac	
31.25-125-200 mg)	D. I.I.	medication(s) available for	
STALEVO 150 (carbidopa-	Parkinson's	There is a generic equival	
levodopa-entacapone tabs	Disease	to your doctor or pharmac	
37.5-150-200 mg)	Parkinson's	medication(s) available for	
STALEVO 200 (carbidopa-	Disease	There is a generic equival	
levodopa-entacapone tabs 50-200-200 mg)	Disease	to your doctor or pharmac	
UKONIQ (umbralisib	Cancor	medication(s) available for	or pharmacist about other
tosylate tab 200 mg)	Cancer	-	
VIMPAT (lacosamide tab 50	Seizures	medication(s) available for	
mg,100 mg, 150 mg, 200	Seizures	There is a generic equival to your doctor or pharmac	
-		medication(s) available for	
mg)		medication(s) available for	your condition.
Performar	ce and Performan	nce Select Drug Lists Excl	usions
metronidazole lotion 0.75%	Rosacea	metronidazole cream	
		0.75%, metronidazole	
		gel 0.75%	
testosterone td gel 20.25	Hypogonadism	testosterone gel pump	
mg/1.25 gm (1.62%), 40.5	, , , , , , , , , , , , , , , , , , ,	1.62%	
mg/2.5 gm (1.62%)			
tretinoin gel 0.025%	Acne	tretinoin cream 0.025%	
	Balanced Dru	Ig List Exclusions	
ACZONE (dapsone gel	Acne	There is a generic equival	ent available. Please talk
7.5%)		to your doctor or pharmac	
		medication(s) available for	
COMBIGAN (brimonidine	Glaucoma,	There is a generic equival	
tartrate-timolol maleate	Ocular	to your doctor or pharmac	
ophth soln 0.2-0.5%)	Hypertension	medication(s) available for	



ZIPSOR (diclofenac	Pain/	There is a generic equivalent available. Please talk	
potassium cap 25 mg)	Inflammation	to your doctor or pharmacist about other	
		medication(s) available for your condition.	
Performance Select Drug List Exclusions			
adapalene-benzoyl peroxide	Acne	tretinoin cream 0.1%	
gel 0.3-2.5%			

¹Third-party brand names are the property of their respective owner. ²This list is not all inclusive. Other medicines may be available in this drug class.

DISPENSING LIMIT CHANGES

The BCBSTX prescription drug benefit program includes coverage limits on certain medications and drug categories. Dispensing limits are based on U.S. Food and Drug Administration (FDA) approved dosage regimens and product labeling. Changes by drug list are listed on the charts below.

Please note: The dispensing limits listed below only apply to select members whose plan has a quarterly updated prescription drug list. BCBSTX members on an annually updated prescription drug list will have these dispensing limits applied on or after Jan. 1, 2023. For BCBSTX members on the 2021 or 2022 Health Insurance Marketplace (HIM) Drug Lists, these dispensing limits may be applied on or after Jan. 1, 2023.

BCBSTX letters all members with a claim for a drug included in the Dispensing Limit Program, regardless of the prescribed dosage. This means members may receive a letter even though their prescribed dosage doesn't meet or exceed the dispensing limit.

Effective June 15, 2022:

Drug Class and Medication(s) ¹	Dispensing Limit(s)	
2021 Health Insurance Marketplace (HIM), 2022 HIM, Performance, Performance Annual and		
Performance Select Drug Lists		
Oxbryta		
Oxbryta (voxelotor)*	90 tablets per 30 days	

¹Third-party brand names are the property of their respective owner. * Not all members may have been notified due to limited utilization.


Effective Sept. 1, 2022:

Drug Class and Medication(s) ¹	Dispensing Limit(s)	
2021 Health Insurance Marketplace (HIM), 2022 HIM, Balanced, Performance,		
Performance Annual and Performance Select Drug Lists		
IL-13 Antagonist		
Adbry (tralokinumab-ldrm)*	4 mL per 30 days	

¹Third-party brand names are the property of their respective owner. * Not all members may have been notified due to limited utilization.

Effective Oct. 1, 2022:

Drug Class and Medication(s) ¹	Dispensing Limit(s)
Basic, Enhanced, Balanced, Performa	nce and Performance Select Drug Lists
Alternative Dosage Form	
Dartisla ODT*	120 tablets per 30 days
Lyvispah (baclofen) 5 mg Granule packet ^{*2}	120 packets per 30 days
Lyvispah (baclofen) 10 mg Granule packet ^{*2}	120 packets per 30 days
Lyvispah (baclofen) 20 mg Granule packet*2	120 packets per 30 days



Valsartan oral solution*	2400 mL per 30 days
Miscellaneous	
Emla (lidocaine-prilocaine) 2.5%-2.5%	60 grams per 30 days
Therapeutic Alternatives	
METAXALONE TAB 400 MG [*]	240 tablets per 30 days
PHOSPHOLINE SOL 0.125%OP*	5 mL per 30 days
Basic, Enhanced, 2021 HIM, 2022 HIM, Balar	nced, Performance, Performance Annual and
Performance S	elect Drug Lists
Cibingo	
Cibinqo (abrocitinib) 50 mg tablets*	30 tablets per 30 days
Cibinqo (abrocitinib) 100 mg tablets*	30 tablets per 30 days
Cibinqo (abrocitinib) 200 mg tablets*	30 tablets per 30 days
Insulin Pumps	
Omnipod DASH kit/Omnipod 5 kit*	1 kit per 720 days
Pyrukynd	
Pyrukynd (mitapivat) Therapy Pack 5 MG*	7 tablets per 365 days
Pyrukynd (mitapivat) Therapy Pack 7 x 20 MG & 7	14 tablets per 365 days
x 5 MG [*]	
Pyrukynd (mitapivat) Therapy Pack 7 x 50 MG & 7	14 tablets per 365 days
x 20 MG*	
Pyrukynd (mitapivat) 5 mg tablets*	56 tablets per 28 days
Durukund (mitaniyat) 20 mg tablata*	56 tablets per 28 days


Pyrukynd (mitapivat) 20 mg tablets*	56 tablets per 28 days
Pyrukynd (mitapivat) 50 mg tablets*	56 tablets per 28 days
Recorlev	
Recorlev (levoketoconazole)*	240 tablets per 30 days
Tarpeyo	
TARPEYO (budesonide)*	120 capsules per 30 days
Basic, Enhanced and	l Balanced Drug Lists
Oxbryta	
Oxbryta (voxelotor)	90 tablets per 30 days
Basic and Enha	inced Drug Lists
IL-13 Antagonist	
Adbry (tralokinumab-ldrm)	4 mL per 30 days
Vuity	
Vuity (pilocarpine HCL) ophthalmic solution	2.5 mL per 30 days

¹Third-party brand names are the property of their respective owner.
 * Not all members may have been notified due to limited utilization.
 ² The target drug Lyvispah is misspelled on the dispensing limits letter for Basic and Enhanced Drug Lists.

Clarification to the July 2022 Quarterly Changes Dispensing Limit Letter

The dispensing limit letter incorrectly listed Edarbi, Edarbyclor and Soolantra as target drugs included in the Therapeutic Alternatives program. These target drugs belong to the Miscellaneous program, effective July 1, 2022.

Letters mailed in late April to impacted members on the Basic, Enhanced, Balanced, Performance and Performance Select Drug Lists. Clarification letters will not be sent to members because the dispensing limits are accurate on the letter and both programs apply to the drug lists mentioned above.



UTILIZATION MANAGEMENT PROGRAM CHANGES

New Target Drugs Added to Existing PA Programs

Effective Oct. 1, 2022, the following changes will be applied:

- Target drugs Dartisla ODT, Valsartan oral solution and Lyvispah (baclofen) granule packet will be added to the Alternative Dosage Form PA program. This change applies to the Performance and Performance Select Drug Lists.*
- Target drug Omnipod DASH kit/Omnipod 5 kit will be added to the Insulin Pumps PA program. This change applies to the 2021 HIM, 2022 HIM, Balanced, Performance, Performance Annual and Performance Select Drug Lists.*

New Programs Added to Select Drug Lists

- Effective **Sept. 1, 2022**, the Interleukin-13 (IL-13) Antagonist Specialty PA program and target drug Adbry (tralokinumab-ldrm) will be added to the 2021 HIM, 2022 HIM, Balanced, Performance, Performance Annual and Performance Select Drug Lists.*
- Effective Oct. 1, 2022, the following changes will be applied:
 - The Cibinqo Specialty PA program and target drug Cibinqo will be added to the 2021 HIM, 2022 HIM, Balanced, Performance, Performance Annual and Performance Select Drug Lists.*
 - The Pyrukynd Specialty PA program and target drug Pyrukynd (mitapivat) will be added to the 2021 HIM, 2022 HIM, Balanced, Performance, Performance Annual and Performance Select Drug Lists.*
 - The Recorlev Specialty PA program and target drug Recorlev (levoketoconazole) will be added to the 2021 HIM, 2022 HIM, Balanced, Performance, Performance Annual and Performance Select Drug Lists.*
 - The Tarpeyo PA program and target drug TARPEYO (budesonide) will be added to the 2021 HIM, 2022 HIM, Balanced, Performance, Performance Annual and Performance Select Drug Lists.*

Members were notified about the PA standard program changes listed in the tables below.

Drug categories added to current pharmacy PA standard programs, effective July 1, 2022:

Drug Category	Targeted Medication(s) ¹
Basic, Basic Annual, Enhanced and Enhanced Annual Drug Lists	
Cibinqo	Cibinqo (abrocitinib) ^{2*}
IL-13 Antagonist	Adbry (tralokinumab-ldrm) ^{2*}

¹*Third-party brand names are the property of their respective owner.*

² Member level PAs were entered through Oct. 1, 2022, for Basic and Enhanced Drug Lists and Jan. 1, 2023, for Basic Annual and Enhanced Annual Drug Lists.
* Not all members may have been notified due to limited utilization.

6



Drug categories added to current pharmacy PA standard programs, effective Oct. 1, 2022*:

Drug Category	Targeted Medication(s) ¹
Basic and Enhanced Drug Lists	
Pyrukynd	Pyrukynd (mitapivat) Therapy Pack 5 MG [*] , Pyrukynd (mitapivat) Therapy Pack 7 x 20 MG & 7 x 5 MG [*] , Pyrukynd (mitapivat) Therapy Pack 7 x 50 MG & 7 x 20 MG [*] , Pyrukynd (mitapivat) 5 mg tablets [*] , Pyrukynd (mitapivat) 20 mg tablets [*] , Pyrukynd (mitapivat) 50 mg tablets [*]
Recorlev	Recorlev (levoketoconazole)*
Тагреуо	TARPEYO (budesonide)*

¹ Third-party brand names are the property of their respective owner.

* Not all members may have been notified due to limited utilization. ** Applies to select members on Oct. 1, 2022. Members on an Annual drug list may not see these changes applied until their 2023 renewal date.

Targeted drugs added to current pharmacy PA standard programs, effective Oct. 1, 2022*:

Drug Category	Targeted Medication(s) ¹	
Basic, Enhanced and Balanced Drug Lists		
Alternative Dosage Form	Dartisla ODT [*] , Lyvispah (baclofen) 5 mg Granule packet [*] , Lyvispah (baclofen) 10 mg Granule packet [*] , Lyvispah (baclofen) 20 mg Granule packet [*] , Valsartan oral solution [*]	
Basic and Enhanced Drug Lists		
Insulin Pumps	Omnipod DASH kit/Omnipod 5 kit*	
Basic, Enhanced, Balanced, Performance and Performance Select Drug Lists		
Therapeutic Alternatives	METAXALONE TAB 400 MG [*] , METFORMIN TAB 625 MG [*] , PHOSPHOLINE SOL 0.125% OP [*] , PREDNISOLONE SOD PHOSPHATE ORAL SOLN 10 MG/5 ML (BASE EQUIV) [*] , VTAMA (tapinarof) 1% CREAM [*]	

¹ Third-party brand names are the property of their respective owner.

** Not all members may have been notified due to limited utilization. ** Applies to select members on Oct. 1, 2022. Members on an Annual drug list may not see these changes applied until their 2023 renewal date.

Per our usual process of member notification prior to implementation, targeted mailings were sent to members affected by drug list revisions and/or exclusions, dispensing limit and prior authorization program changes. For the most up-to-date drug list and list of drug dispensing limits, visit the Pharmacy Program section of our Provider website.

If your patients have any questions about their pharmacy benefits, please advise them to contact the number on their member ID card. Members may also visit bcbstx.com and log in to Blue Access for MembersSM (BAMSM) or MyPrime.com for a variety of online resources.



Change in Benefit Coverage for Select High Cost Products

Several high cost products with available lower cost alternatives will be excluded on the pharmacy benefit for select drug lists. This change impacts BCBSTX members who have prescription drug benefits administered by Prime Therapeutics. This change is part of an ongoing effort to make sure our members and employer groups have access to safe, cost-effective medications.

High cost products that either are new to market or have therapeutic equivalents available have also been excluded. Please note: Members were not notified of these changes because there is no utilization or the pharmacist can easily fill a member's prescription with the equivalent without needing a new prescription from the doctor. The following drugs are excluded on select drug lists:

Product(s) No Longer Covered ^{1*}	Condition Used For	Covered Alternative(s) ^{1,2}
DICLOFENAC TAB 25 MG	PAIN	DICLOFENAC POT 50 MG, MELOXICAM, IBUPROFEN, NAPROXEN
METFORMIN TAB 625 MG	DIABETES	METFORMIN 500 MG TABS
ORPHENADRINE W/ ASPIRIN & CAFFEINE TAB 25-385-30 MG	MUSCLE PAIN	CYCLOBENZAPRINE, ORPHENADRINE

1 All brand names are the property of their respective owners.

2 This list is not all-inclusive. Other products may be available.

* This chart applies to members on the Basic, Basic Annual, Multi-Tier Basic, Multi-Tier Basic Annual, Enhanced, Enhanced Annual, Multi- Tier Enhanced and Multi-Tier Enhanced Annual Drug Lists.

Split Fill Program Category Expansion

Starting on Jan. 1, 2023, the Split Fill Program will be expanded to include additional categories beyond oral oncology medications, such as multiple sclerosis and iron toxicity.

Reminder:

BCBSTX offers its members and groups a Split Fill Program to reduce waste and help avoid costs of select specialty medications that may go unused. Members new to therapy (or have not had claims history within the past 120 days for the drug) are provided partial, or "split," prescription fills for up to three months.

The Split Fill Program applies to a specific list of drugs known to have early discontinuation or dose modification. You can view the current list of drugs and find more information on the <u>Split Fill Program</u> on our Provider website.

Please call the number on the member's ID card to verify coverage, or for further assistance or clarification on your patient's benefits.

Prime Therapeutics LLC is a pharmacy benefit management company. BCBSTX contracts with Prime to provide pharmacy benefit management and related other services. BCBSTX, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime. MyPrime.com is an online resource offered by Prime Therapeutics.

The information mentioned here is for informational purposes only and is not a substitute for the independent medical judgment of a physician. Physicians are to exercise their own medical judgment. Pharmacy benefits and limits are subject to the terms set forth in the member's certificate of coverage which may vary from the limits set forth above. The listing of any particular drug or classification of drugs is not a guarantee of benefits. Members should refer to their certificate of coverage for more details, including benefits, limitations and exclusions. Regardless of benefits, the final decision about any medication is between the member and their health care provider.